Abstract IA26: Combined PARP and immune checkpoint inhibition in ovarian cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.ovca19-ia26
Abstract: Ovarian cancer (OC) is one of the few malignancies in which immunotherapy with immune checkpoint inhibitors exhibits only modest activity and currently has no FDA-approved indication. Therefore, the development of strategies to improve the efficacy… read more here.
Keywords: immune checkpoint; combined parp; parp immune; ovarian cancer ... See more keywords